n3D seeks to create the industry-leading standard for 3D, in vitro cell culturing and to apply this disruptive technology to life science research and development, drug discovery, toxicology and regenerative medicine.
This vision will be realized 3 phases:
Phase I. This phase provides basic cell-culturing solutions for life science research and development. It is close to completion and has provided initial revenue, technology validation, scientific publications, and establishment of our brand identity. The various formats of the Bio-Assembler™ are commercially available. n3D currently has customers worldwide and distributors in the US (MidSci), Japan (Funakoshi), and Europe (Novusci). A Phase I and II SBIR grant from the National Science Foundation has been awarded to develop a product for toxicology laboratories for cosmetics, pharmaceutical and environmental monitoring. A major component of the Phase I strategy has been successfully executed, which is to have laboratories worldwide adopt the Bio-Assembler™ and publish their results in peer review publications. Resources raised in this round will be used for sales and marketing to continue to grow this product line.
Phase II. The Phase II strategy is to adapt and market n3D’s technology for high-throughput applications in toxicology testing and drug discovery. Because of the Bio-Assembler™’s high-throughput potential and its better representation of in vivo tissue, this platform can replace 2D culturing as the standard for the initial phases of drug discovery. This phase has been initiated by the creation of large-scale, high-throughput versions of the Bio-Assembler™. The commercialization of these systems will create the opportunity for partnering with an automated culturing and screening device manufacturer. n3D is in the process of final validation of a proprietary system which will offer a compact and complete solution. This system uses the simplicity of Apple’s iPod Touch or iPhone technology and Apps to incorporate imaging and data analysis capabilities into a single device (the n3Dock™ station). A major component of this Phase II strategy is to expand sales and marketing on an international scale, with special focus in Brazil, Japan, Singapore, and Europe.
Phase III. The Bio-Assembler™ represents a new paradigm in scaffold-less cell culturing with temporal and spatial control of tissue structure. This has great potential for regenerative medicine and stem cell therapy. Research conducted with the support of federal grants or long-horizon venture funding will optimize the basic Bio-Assembler™ device and establish the procedures necessary for growing specific tissue types. This will consolidate an intellectual property position, after which n3D will seek partners with expertise in these areas to develop products for therapeutic applications.